Bo Huang

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

E. Schmidt, A. Tolcher, M. Sznol, 2017, Clinical Cancer Research.

Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor

A. Jimeno, K. Kern, W. Messersmith, 2018, Annals of Surgical Oncology.

Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies

L. Tian, Lee-Jen Wei, T. Choueiri, 2020, Annals of Internal Medicine.

The influence of intraoperative pleural perfusion with matrine–cisplatin or cisplatin on stromal cell-derived factor-1 in non-small cell lung cancer patients with subclinical pleural metastasis

Yixue Xue, Bo Huang, Chengliang Yang, 2012, Medical Oncology.

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.

C. Burton, J. Radford, A. Santoro, 2021, Blood advances.

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Craig B. Davis, R. Houot, X. Mu, 2020, Clinical Cancer Research.

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study

J. Radford, A. Santoro, S. Ansell, 2021, Targeted Oncology.

Quantifying Immunoscore performance

Lee-Jen Wei, D. H. Kim, L. Nie, 2018, The Lancet.

Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study

L. Tian, Lee-Jen Wei, M. Rothenberg, 2018, JAMA oncology.

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.

L. Saltz, A. Venook, L. Fong, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.